Abstract Number: 2113 • ACR Convergence 2022
Improvement in Key PsA Core Domains with Guselkumab Treatment in an Enriched Population of ACR20 Non-Responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies
Background/Purpose: Despite available PsA treatments, a portion of PsA patients (pts) does not achieve improvements in PsA signs and symptoms according to ACR response criteria.…Abstract Number: 0168 • ACR Convergence 2022
Semiquantitative Thigh Magnetic Resonance Imaging (tMRI) in Determining Skeletal Muscle Outcomes at Baseline and on Follow up in Idiopathic Inflammatory Myopathies (IIMs)
Background/Purpose: Semiquantitative scoring of thigh Magnetic Resonance Imaging (tMRI) has shown contradictory results in associating muscle inflammation, damage, and clinically assessed muscle weakness. Moreover, there…Abstract Number: 0392 • ACR Convergence 2022
Performance of Clinical, Laboratory and Imaging Features for the Diagnosis of Axial Spondyloarthritis – A Systematic Literature Review
Background/Purpose: The Berlin algorithm for the diagnosis of axial spondyloarthritis (axSpA) was developed more than 15 years ago (2004). Since then, new studies suggest that…Abstract Number: 0858 • ACR Convergence 2022
Predicting the Occurrence of Drug-Free Inactive Disease Two Years After Diagnosis of Non-Systemic Juvenile Idiopathic Arthritis
Background/Purpose: The goal of treatment for juvenile idiopathic arthritis (JIA) is inactive disease (ID), but the optimal treatment for each patient to maximize ID and…Abstract Number: 1260 • ACR Convergence 2022
Tenderness and Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis
Background/Purpose: In inflammatory arthritis swelling is regarded as a sign of synovitis and is associated with radiographic progression. However, the association of tenderness with radiographic…Abstract Number: 1496 • ACR Convergence 2022
Do Patients in MDA Report Low Disease Activity Regardless of Which of the MDA Criteria Are Met?
Background/Purpose: The Minimal Disease Activity (MDA) criteria evaluate PsA disease activity and response to treatment and are defined as meeting ≥5 criteria: tender joint count…Abstract Number: 1952 • ACR Convergence 2022
Burden of Disease in Refractory Rheumatoid Arthritis
Background/Purpose: Despite major advances in RA treatment and the improved outcomes that have been associated with the expanding number of advanced therapies available, a substantial…Abstract Number: 2138 • ACR Convergence 2022
Real-world Persistence and Treatment Patterns in Psoriatic Arthritis Patients Treated with Anti-IL17 Therapy
Background/Purpose: Interleukin-17A inhibitors (anti-IL17) have provided an additional treatment option in the management of the psoriatic arthritis (PsA). This study aims to describe the patient…Abstract Number: 0172 • ACR Convergence 2022
Clinical Characteristics and Outcomes of Inflammatory Myositis Related Interstitial Lung Disease: A 15 Year Retrospective Study
Background/Purpose: Interstitial lung disease (ILD) is a common complication of Idiopathic Inflammatory Myopathy (IIM). This extra-muscular manifestation is a significant source of morbidity and has…Abstract Number: 0418 • ACR Convergence 2022
Real World Evidence on Disease Activity in Patients with Ankylosing Spondylitis Treated with Tumour Necrosis Factor Inhibitors and/or Nonsteroidal Anti-Inflammatory Drugs in Routine Care
Background/Purpose: Ankylosing Spondylitis (AS) is an inflammatory rheumatic disease affecting the axial skeleton (1), with a prevalence of up to 0.5% in Europe (2; 3),…Abstract Number: 0890 • ACR Convergence 2022
Long Term Efficacy of a 2-year MRI Treat-to-target Treatment Strategy on Disease Activity, MRI Inflammation and Physical Function in Rheumatoid Arthritis Patients in Clinical Remission: Five Year Follow-up of the IMAGINE-RA Cohort
Background/Purpose: Targeting MRI remission in rheumatoid arthritis (RA) patients in clinical remission may improve long term clinical, functional and MRI outcomes. The purpose of the…Abstract Number: 1261 • ACR Convergence 2022
Scoring Structural Damage in Rheumatoid Arthritis by Ultrasound: Results from a Delphi Process and Web-Based Reliability Exercise by the OMERACT Ultrasound Working Group
Background/Purpose: Structural damage in rheumatoid arthritis (RA) includes bone erosions, cartilage changes, and joint malalignment; historically evaluated with conventional radiography. Ultrasound (US) has been shown…Abstract Number: 1499 • ACR Convergence 2022
The Impact of Cycling Among Tumor Necrosis Factor Inhibitors on Disease Control in Patients with Axial Spondyloarthritis: A Study from the CorEvitas PsA/SpA Registry
Background/Purpose: Axial spondyloarthritis (AxSpA) is a chronic inflammatory disease characterized by inflammatory back pain, morning stiffness, and reduced functional capacity. Approved therapies for AxSpA include…Abstract Number: 1960 • ACR Convergence 2022
Impact of Delaying Initiation of Methotrexate by One Month on the Outcome of RA at One Year
Background/Purpose: It is recommended that vaccinations should be performed prior to start methotrexate (MTX) knowing that delaying initiation of background therapy may have an impact…Abstract Number: 2139 • ACR Convergence 2022
Sustained Response to Guselkumab Regardless of Baseline Demographic, Disease, and Medication Characteristics in Patients with Active Psoriatic Arthritis and an Inadequate Response to TNF Inhibitors: Results from a Phase 3b Trial
Background/Purpose: Guselkumab (GUS) is a human monoclonal antibody targeting the IL-23 p19 subunit. In the Phase 3b COSMOS trial (NCT03796858), GUS significantly improved disease signs/symptoms…
- « Previous Page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- …
- 49
- Next Page »